Celcuity Inc. (CELC): Price and Financial Metrics


Celcuity Inc. (CELC): $15.10

0.60 (+4.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CELC Stock Price Chart Interactive Chart >

Price chart for CELC

CELC Price/Volume Stats

Current price $15.10 52-week high $33.01
Prev. close $14.50 52-week low $8.75
Day low $14.01 Volume 26,500
Day high $15.59 Avg. volume 159,157
50-day MA $17.63 Dividend yield N/A
200-day MA $20.82 Market Cap 225.20M

Celcuity Inc. (CELC) Company Bio


Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.


CELC Latest News Stream


Event/Time News Detail
Loading, please wait...

CELC Latest Social Stream


Loading social stream, please wait...

View Full CELC Social Stream

Latest CELC News From Around the Web

Below are the latest news stories about Celcuity Inc that investors may wish to consider to help them evaluate CELC as an investment opportunity.

Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development

MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced the addition of two senior executives to its corporate management team.

Yahoo | November 29, 2021

Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial

MINNEAPOLIS, MN / ACCESSWIRE / November 15, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer to provide Ibrance® (palbociclib) for use in Celcuity's Phase 3 clinical trial at no cost to Celcuity.

Yahoo | November 15, 2021

Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences

MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in virtual meetings with investors at the following conferences: * 12th Annual Craig-Hallum Alpha Select Conference on November 16, 2021; and * Jefferies London

Yahoo | November 9, 2021

Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

PTMINNEAPOLIS, MN / ACCESSWIRE / November 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced financial results for the third quarter ended September 30, 2021 and summarized recent business progress.

Yahoo | November 8, 2021

Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call

MINNEAPOLIS, MN / ACCESSWIRE / October 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the third quarter 2021 after the stock market close on Monday, November 8, 2021.

Yahoo | October 29, 2021

Read More 'CELC' Stories Here

CELC Price Returns

1-mo -21.88%
3-mo -33.16%
6-mo -43.85%
1-year 51.76%
3-year -43.87%
5-year N/A
YTD 64.85%
2020 -13.91%
2019 -55.65%
2018 26.60%
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9538 seconds.